The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer
- Authors
- Kim, Hee Jung; Eoh, Kyung Jin; Kim, Lee Kyung; Nam, Eun Ji; Yoon, Sun Och; Kim, Kun-Hong; Lee, Jae Kwan; Kim, Sang Wun; Kim, Young Tae
- Issue Date
- 13-12월-2016
- Publisher
- IMPACT JOURNALS LLC
- Keywords
- HOXA11 antisense; long noncoding RNA; invasion; prognosis; cervical cancer
- Citation
- ONCOTARGET, v.7, no.50, pp.83001 - 83016
- Indexed
- SCIE
SCOPUS
- Journal Title
- ONCOTARGET
- Volume
- 7
- Number
- 50
- Start Page
- 83001
- End Page
- 83016
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/86547
- DOI
- 10.18632/oncotarget.12863
- ISSN
- 1949-2553
- Abstract
- Recent research has focused on the impact of long noncoding RNA (lncRNA) in cervical carcinogenesis. However, whether HOXA11 antisense (HOXA11-AS) is involved in cervical cancer remains to be elucidated. In the present study, we examined HOXA11-AS expression levels in cervical cancer patients and determined the relationships between HOXA11-AS expression and clinicopathological factors. We also investigated the bio-functional consequences of HOXA11-AS overexpression both in vitro and in vivo. HOXA11-AS expression was significantly greater in tissues from patients with cervical cancer than in control patients (P< 0.001). Multivariate analysis showed that high HOXA11-AS was an independent prognosticator of overall survival (Hazard ratio=2.450, P=0.032). HOXA11-AS overexpression enhanced cell proliferation, migration, and tumor invasion in vitro, whereas HOXA11-AS knockdown inhibited these biologic aggressive features. These adverse changes were accompanied by characteristics of epithelial-mesenchymal transition (EMT). In vivo xenograft experiments using the siHOXA11-AS-transfected HeLa cells revealed that HOXA11-AS strongly induced tumor growth. Furthermore, we found that HOXA11-AS knockdown decreased cancer stemness and triggered the EMT program. In conclusion, HOXA11-AS overexpression correlated with poor survival in patients with cervical cancer. Thus, HOXA11-AS may be a pivotal target for exploring novel cervical cancer therapeutics.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/86547)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.